37
Participants
Start Date
September 30, 2007
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
ranibizumab
Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
Tennessee Retina, P.C., Nashville
Collaborators (1)
Genentech, Inc.
INDUSTRY
Brandon G. Busbee, MD
OTHER